Lilly strengthens abemaciclib case in CDK 4/6 market race

4 June 2017

US pharma major Eli Lilly (NYSE: LLY) has added to its body of data on abemaciclib in breast cancer as it seeks to gain ground on rivals in the cyclin-dependent kinase (CDK) 4 and 6 inhibitor space.

The company has formidable competition in the field, with Ibrance (palbociclib) from US pharma giant Pfizer (NYSE: PFE) and Kisqali (ribociclib) both already approved in the USA.

"One of our goals is not to replicate studies, but to further innovate in the field of CDK4 and 6 inhibition and advance potential treatment options for patients wherever they may be in the course of their disease"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK